The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion, cytokine secr...

Full description

Bibliographic Details
Main Authors: Antje Tunger, Ulrich Sommer, Rebekka Wehner, Anne Sophie Kubasch, Marc-Oliver Grimm, Michael Philipp Bachmann, Uwe Platzbecker, Martin Bornhäuser, Gustavo Baretton, Marc Schmitz
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Journal of Clinical Medicine
Subjects:
cancer immunotherapy
immune monitoring
immune checkpoints
programmed cell death protein 1
programmed cell death 1 ligand 1
Online Access:https://www.mdpi.com/2077-0383/8/10/1534

Internet

https://www.mdpi.com/2077-0383/8/10/1534

Similar Items